Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

375
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
375
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

374
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
374
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

109
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
109
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

374
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
374

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Measuring patriotic emotional granularity: task-based validation, brief scale development, and cross-method evidence.

BMC psychology·2026
Same author

Should we screen for colorectal cancer with biennial FIT beginning at age 45 in Canada?

Journal of the Canadian Association of Gastroenterology·2026
Same author

MGDP: Mastering a Generalized Depth Perception Model for Quadruped Locomotion.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Saudi consensus statements on the management of irritable bowel syndrome.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association·2026
Same author

Future Global Outlook in Gastrointestinal and Liver Disorders: Consensus and Perspectives from the Leaders of Member Societies of the World Gastroenterology Organization.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

Immunomodulatory effects of biodegradable Mg-Cu-Zn alloy in esophageal cancer.

Bioactive materials·2026

Video Experimental Relacionado

Updated: Jun 23, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K

Enfermedad de la úlcera péptica

Majid A Almadi1, Yidan Lu2, Ali A Alali3

  • 1Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia; Division of Gastroenterology, The McGill University Health Center, Montréal General Hospital, McGill University, Montréal, QC, Canada.

Lancet (London, England)
|June 17, 2024
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de úlcera péptica, a menudo causada por H. pylori o medicamentos, se maneja con supresión ácida y erradicación de H. pylori. El uso adecuado de inhibidores de la bomba de protones (IPP) es clave, y se considera la retirada de la prescripción cuando ya no esté indicada.

Más Videos Relacionados

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

305

Videos de Experimentos Relacionados

Last Updated: Jun 23, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

305

Área de la Ciencia:

  • Gastroenterología
  • Médico interno
  • Farmacología

Sus antecedentes:

  • La enfermedad de la úlcera péptica (PUD, por sus siglas en inglés) afecta al 0,12- 1,5% anual.
  • Las causas comunes incluyen infección por Helicobacter pylori, uso de AINE/aspirina, enfermedad crítica o factores idiopáticos.
  • El tratamiento implica la erradicación de H. pylori, la supresión del ácido (a menudo inhibidores de la bomba de protones) y el tratamiento de complicaciones como el sangrado.

Objetivo del estudio:

  • Revisar las estrategias actuales de tratamiento de la enfermedad de úlcera péptica.
  • Discutir las consideraciones especiales para los pacientes tratados con agentes antiplaquetarios o antitrombóticos.
  • Para resaltar la evolución de las pautas de tratamiento y profilaxis de H. pylori.

Principales métodos:

  • Revisión de la literatura sobre las directrices y la investigación en materia de gestión de la PUD.
  • Análisis de los métodos de tratamiento de la infección por H. pylori y supresión ácida.
  • Examen de las indicaciones para la profilaxis y las terapias emergentes.

Principales resultados:

  • La elección del tratamiento para H. pylori depende de la resistencia local a los antibióticos.
  • Los IBP se recomiendan para la profilaxis en pacientes de alto riesgo.
  • Los bloqueadores ácidos competitivos para el potasio y la vacunación contra H. pylori son áreas para futuras investigaciones.

Conclusiones:

  • El uso adecuado de los IPP para las indicaciones aprobadas supera generalmente los riesgos.
  • Se debe considerar la supresión de la prescripción de IBP cuando se resuelva la indicación.
  • Se necesita más investigación para el manejo de la hemorragia de la úlcera por estrés y la selección óptima del paciente/tratamiento.